Clinical Trials
Below are current clinical trials.
269 studies in Infectious Diseases Research (all studies, either open or closed).
Filter this list of studies by location, status and more.
-
Rochester, Minn.
The purpose of this study is to evaluate the real-world utilization of ceftolozane/tazobactam (C/T) and to assess patient outcomes.
-
Rochester, Minn.
This study includes collection of blood samples from the healthy controls and those with suspected bloodstream infections.
-
Rochester, Minn.
The purpose of this study is to evaluate the clinical outcomes, survivorship, and complications of HIV-positive patients undergoing total hip or total knee arthroplasty at the Mayo Clinic in the past 20 years.
-
Scottsdale/Phoenix, Ariz.
This study will evaluate the effect of presatovir on respiratory syncytial virus (RSV) viral load in autologous or allogeneic hematopoietic cell transplant (HCT) recipients with an acute RSV lower respiratory tract infection (LRTI), the effect of presatovir on being free of any supplemental oxygen, and rates of respiratory failure and all-cause mortality, and pharmacokinetics (PK), safety, and tolerability of presatovir.
-
Rochester, Minn.
The purpose of this study is to evaluate the potential effectiveness of losartan (100mg daily) for reducing inflammation and improving immune recovery in patients with HIV.
-
Jacksonville, Fla., Rochester, Minn.
The purpose of this study is to determine whether INO-8000 alone or in combination with INO-9012 (IL-12) is safe and induces a Hepatitis C virus-specific immune response.
-
Scottsdale/Phoenix, Ariz.
This study will evaluate efficacy and safety information about RBX2660 for the treatment of recurrent Clostridium difficile infection (CDI). Enrolled subjects will receive one treatment with RBX2660 (microbiota suspension).
-
Jacksonville, Fla.
This is a prospective, multicenter, randomized, double-blinded, placebo-controlled Phase 3 study of a microbiota suspension of intestinal microbes. Patients who have had at least two recurrences after a primary episode and have completed at least two rounds of standard-of-care oral antibiotic therapy or have had at least two episodes of severe CDI resulting in hospitalization within the last year may be eligible for the study. Subjects who are deemed failures following the blinded treatment per the pre-specified treatment failure definition may elect to receive an unblinded RBX2660 enema.
-
Rochester, Minn.
The purpose of this study is to determine if extracellular (EV) counts and content can differentiate Alcoholic Hepatitis (AH) from alcoholic liver disease as well as end stage liver disease due to other causes.
-
Rochester, Minn.
This is the first prospective, multi-center, double-blinded, randomized controlled study of a microbiota suspension derived from intestinal microbes. Patients who have had at least two recurrences of C. difficile infection (CDI) after a primary episode and have completed at least two rounds of standard-of-care oral antibiotic therapy or have had at least two episodes of severe CDI resulting in hospitalization may be eligible for the study. Patients whose CDI returns in less than 8 weeks after the last assigned study treatment may be eligible to receive up to 2 treatments with RBX2660 in the open-label portion of the study.